Harald Reinhart Biography and Net Worth

Insider of Zai Lab

Harald Reinhart, M.D., has been our Chief Medical Officer, Autoimmune & Infectious Disease since 2017. He is currently Adjunct Clinical Professor of infectious diseases at Yale School of Medicine. Prior to joining Zai Lab, Dr. Reinhart worked at Shionogi US as Head of Clinical Development and Medical Affairs, directing a broad portfolio of antibiotics, diabetes, allergy and pain medications. He guided several compounds through regulatory meetings, and obtained approval for ospemifene. Between 2003 and 2011, he held senior roles at Novartis where he oversaw successful filings of SNDAs and NDAs for Coartem, Famvir, Sebivo, and Cubicin, managed clinical development groups for infectious disease, immunity, transplantation, and renal disease. He supervised the transitioning of research projects into clinical developmenmt. In the years before, he was International Clinical Project Manager in charge of ciprofloxacin and acarbose at Bayer Corp., with several successful SNDAs and approvals.

Dr. Reinhart holds a medical degree from the University of Würzburg in Germany where he trained in anesthesiology. He completed his medical specialty training in the United States with board-certifications in internal medicine and infectious diseases.

What is Harald Reinhart's net worth?: The estimated net worth of Harald Reinhart is at least $1.66 million as of June 26th, 2024. Dr. Reinhart owns 62,619 shares of Zai Lab stock worth more than $1,655,020 as of November 23rd. This net worth approximation does not reflect any other investments that Dr. Reinhart may own. Learn More about Harald Reinhart's net worth.
How do I contact Harald Reinhart?: The corporate mailing address for Dr. Reinhart and other Zai Lab executives is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. Zai Lab can also be reached via phone at 862161632588 and via email at [email protected]. Learn More on Harald Reinhart's contact information.
Has Harald Reinhart been buying or selling shares of Zai Lab?: Harald Reinhart has not been actively trading shares of Zai Lab over the course of the past ninety days. Most recently, Harald Reinhart sold 7,431 shares of the business's stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $17.90, for a transaction totalling $133,014.90. Following the completion of the sale, the insider now directly owns 62,619 shares of the company's stock, valued at $1,120,880.10. Learn More on Harald Reinhart's trading history.
Who are Zai Lab's active insiders?: Zai Lab's insider roster includes Rafael Amado (President, Head of Global Research and Development), Kai-Xian Chen (Director), Yajing Chen (CFO), William Cho (CFO), John Diekman (Director), Ying Du (CEO), Frazor Edmondson, III (Insider), Tao Fu (COO), William Lis (Director), Harald Reinhart (Insider), Joshua Smiley (Insider), and Peter Wirth (Director). Learn More on Zai Lab's active insiders.
Are insiders buying or selling shares of Zai Lab?: During the last twelve months, Zai Lab insiders bought shares 1 times. They purchased a total of 4,000 shares worth more than $119,600.00. During the last twelve months, insiders at the sold shares 15 times. They sold a total of 105,597 shares worth more than $2,125,230.82. The most recent insider tranaction occured on August, 16th when insider Joshua L Smiley sold 4,352 shares worth more than $72,547.84. Insiders at Zai Lab own 13.9% of the company. Learn More about insider trades at Zai Lab.
Information on this page was last updated on 8/16/2024.

Harald Reinhart Insider Trading History at Zai Lab

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/26/2024	Sell	7,431	$17.90	$133,014.90	62,619
3/3/2023	Sell	11,480	$40.00	$459,200.00	18,958
11/15/2022	Sell	1,854	$40.00	$74,160.00	24,861
9/7/2021	Sell	10,000	$150.93	$1,509,300.00
8/24/2021	Sell	8,000	$143.36	$1,146,880.00
7/13/2021	Sell	8,000	$169.92	$1,359,360.00
6/16/2021	Sell	8,000	$162.71	$1,301,680.00	8,000
5/25/2021	Sell	8,000	$161.66	$1,293,280.00	8,000
4/21/2021	Sell	16,000	$156.10	$2,497,600.00	8,000

Harald Reinhart Buying and Selling Activity at Zai Lab

Zai Lab Company Overview

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

Today's Range

Now: $26.43

$25.16

$26.66

50 Day Range

MA: $26.48

$20.34

$33.18

2 Week Range

Now: $26.43

$13.48

$36.60

Volume

790,653 shs

Average Volume

714,676 shs

Market Capitalization

$2.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04

Shocking footage from Bill Gates’ $100,000,000,000 AI Bet

From Brownstone Research | Ad

If you missed out on Nvidia, watch this video I just made.

Click here for full details.